Claims:

1. A T cell, optionally isolated, comprising exogenous nucleic acid encoding a T Cell Receptor (TCR) specific for a hepatitis B virus, wherein the T cell is a non-activated T cell which is capable of inhibiting replication of the virus in a cell infected with the said virus, wherein the T cell displays reduced cytotoxicity against the cells infected with, or comprising a peptide of, the said virus.

2. The T cell according to claim 1, wherein the non-activated T cell does not display increased expression of perforin and/or granzyme in response to stimulation with peptide for which the TCR is specific.

3. The T cell according to claim 1 or claim 2, which displays reduced cytotoxicity against cells infected with, or comprising a peptide of, the virus as compared to an activated T cell comprising a TCR specific for the virus which is not modified for reduced expression or activity of a cytotoxic factor.

4. A method, optionally an *in vitro* method, for producing a modified T cell specific for a virus, the method comprising modifying a T cell to express or comprise a T Cell Receptor (TCR) specific for the hepatitis B virus, wherein the modified T cell is a non-activated T cell which is capable of inhibiting replication of the virus in a cell infected with the said virus, wherein the T cell displays reduced cytotoxicity against the cells infected with, or comprising a peptide of, the said virus.

5. The method according to claim 4, wherein modifying the T cell to express or comprise a TCR specific for the virus comprises introducing nucleic acid encoding a TCR specific for the virus into the T cell.

6. The method according to claim 5, wherein the nucleic acid is introduced into the T cell by transduction, transfection or transposon-based system, optionally retroviral transduction or mRNA electroporation.

7. A T cell, optionally isolated, wherein the T cell is obtained or obtainable by the method according to any one of claims 4 to 6.

8. A pharmaceutical composition comprising a T cell according to any one of claims 1 to 3 or claim 7, and a pharmaceutically acceptable carrier, adjuvant, excipient, or diluent.

9. The T cell according to any one of claims 1 to 3 or claim 7, or the pharmaceutical composition according to claim 8 for use in a method of treating or preventing a disease or disorder which is caused or exacerbated by hepatitis B virus (HBV) infection.

10. Use of the T cell according to any one of claims 1 to 3 or claim 7, or the pharmaceutical composition according to claim 8 in the manufacture of a medicament for use in a method of treating or preventing a disease or disorder which is caused or exacerbated by hepatitis B virus (HBV) infection.

11. A method of treating or preventing which is caused or exacerbated by hepatitis B virus (HBV) infection, comprising administering to a subject a therapeutically or prophylactically effective amount of the T cell according to any one of claims 1 to 3 or claim 7, or the pharmaceutical composition according to claim 8.

12. A method of treating or preventing a disease or disorder which is caused or exacerbated by hepatitis B virus (HBV) infection in a subject, comprising:

(a) isolating at least one T cell from a subject;

(b) modifying the at least one T cell to express or comprise a T Cell Receptor (TCR) specific for a virus; and

(c) administering the modified at least one T cell to the subject;

wherein the modified at least one T cell is a non-activated T cell which is capable of inhibiting replication of the virus in a cell infected with the said virus, wherein the T cell displays reduced cytotoxicity against the cells infected with, or comprising a peptide of, the said virus.

13. The method according to claim 12, wherein modifying the at least one T cell to express or comprise a TCR specific for a virus comprises introducing nucleic acid encoding a TCR specific for a virus into the at least one T cell.

14. The method according to claim 13, wherein the nucleic acid is introduced into the at least one T cell by transduction, transfection or transposon-based system.

15. The T cell for use, the use, or the method according to any one of claims 10 to 14, wherein the disease or disorder which is caused or exacerbated by HBV infection is selected from acute hepatitis, fulminant hepatic failure, chronic hepatitis, cirrhosis, liver cancer, hepatocellular carcinoma (HCC) and pancreatic cancer.

16. A kit of parts comprising a predetermined quantity of the T cell according to any one of claims 1 to 3 or claim 7, or the pharmaceutical composition according to claim 8.